H.C. Wainwright cuts Aardvark Therapeutics price target on trial termination
H.C. Wainwright reduced its price target for Aardvark Therapeutics (NASDAQ:AARD) to $4.00 from $6.00, citing FDA's clinical hold on ARD-101 trials. The stock is down 15% in a week and 71% year-to-date. Aardvark is assessing unblinded data and discussing next steps with the FDA. The firm anticipates a delayed timeline for market entry.
How this was made
The 30-second read
Why it matters
The termination removes a major development milestone, prompting H.C. Wainwright to lower its price target, which may trigger short‑term selling pressure.
Market read
The news directly affects AARD shareholders and may influence sentiment across small‑cap biotech stocks.
What to watch
Potential partnership or licensing of the unblinded data could provide upside not reflected in the price target.
Background
Aardvark Therapeutics (NASDAQ:AARD) had a full clinical hold on its IND and recently terminated its Phase 3 HERO and open‑label extension trials for ARD‑101.
Ticker impact
H.C. Wainwright cut its price target on Aardvark Therapeutics after the company terminated its Phase 3 HERO and OLE trials.
likely downward pressure as investors price in the halted program and reduced upside.
Analyst downgrade combined with the termination of pivotal trials removes a key catalyst, increasing downside risk.
Market effects
Biotech sector may see broader risk aversion as trial failures raise concerns about similar programs.
U.S. biotech stocks could face modest sell pressure in the short term.
Limited to investors tracking clinical-stage biotech companies.
Counterpoint
If the company can repurpose ARD-101 data for other indications, the stock may rebound.
Key entities
- companyAardvark Therapeutics
Clinical‑stage biotech developing ARD‑101 for Prader‑Willi Syndrome.
- analyst_firmH.C. Wainwright
Equity research firm that reduced AARD's price target.
